IP Library Granted Patent US 8,557,867
Granted Patent B2
US 8,557,867 · App. 12/665,853 · Granted Oct 15, 2013

Inhibitors of NC

Inventor: J. Marc Simard (Baltimore, MD)
Assignees: The United States of America as Represented by the Department of Veterans Affairs; University of Maryland, Baltimore
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,557,867
App. No.
12/665,853
Granted
Oct 15, 2013
Kind
B2
Abstract

Methods and compositions are provided that are utilized for treatment and/or prevention of intraventricular hemorrhage or progressive hemorrhagic necrosis (PHN), particularly following spinal cord injury. In particular, the methods and compositions are inhibitors of a particular NCca-ATP channel and include, for example, inhibitors of SUR1 and/or inhibitors of TRPM4. Kits for treatment and/or prevention of intraventricular hemorrhage or progressive hemorrhagic necrosis (PHN), particularly following spinal cord injury, are also provided. The present invention also concerns treatment and/or prevention of intraventricular hemorrhage in infants, including premature infants utilizing one or more inhibitors of the channel is provided to the infant, for example to brain cells of the infant.

Claims (8)

1. A method of treating or preventing intraventricular hemorrhage in the brain of an infant at risk for developing intraventricular hemorrhage, comprising administering an effective amount of an inhibitor of NC Ca-ATP channel to the mother prior to birth, wherein the NC Ca-ATP channel inhibitor is glibenclamide.

2. The method of claim 1 , wherein the inhibitor is provided to the mother prior to 37 weeks of gestation.

3. The method of claim 1 , wherein the mother is at risk for premature labor.

4. The method of claim 1 , wherein the pregnancy is less than 37 weeks in gestation and the mother has one or more symptoms of labor.

5. The method of claim 1 , wherein said inhibitor is provided intravenously, subcutaneously, intramuscularly, intracutaneously, or intragastrically.

6. The method of claim 1 , further comprising administering MgADP to the individual.

7. The method of claim 1 , wherein said inhibitor is provided intravenously.

8. The method of claim 1 , further comprising determining the effective amount of the inhibitor to be provided to the mother.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT ASSIGNEE NAME FROM UNIVERSITY OF MARYLAND TO UNIVERSITY OF MARYLAND, BALTIMORE PREVIOUSLY RECORDED ON REEL 023888, FRAME 0773. ASSIGNOR'S HEREBY CONFIRMS THE ENTIRE RIGHT TITLE AND INTEREST. Recorded Oct 7, 2013
From: SIMARD, J. M.
To: MARYLAND, BALTIMORE, UNIVERSITY OF
Reel/Frame 031378/0668 →
ASSIGNMENT OF JOINT UNDIVIDED RIGHT, TITLE AND INTEREST Recorded Mar 20, 2012
From: UNIVERSITY OF MARYLAND, BALTIMORE
To: THE U.S. OF AMERICA AS REPRESENTED BY THE DEPT OF VETERANS AFFAIRS
Reel/Frame 027893/0001 →
CONFIRMATORY LICENSE Recorded May 3, 2010
From: UNIVERSITY OF MARYLAND BALT PROF SCHOOL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024327/0477 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2010
From: SIMARD, J. M.
To: UNIVERSITY OF MARYLAND
Reel/Frame 023888/0773 →
Continuity (4)
Provisional Application 60945636 · Jun 22, 2007
Provisional Application 60945811 · Jun 22, 2007
Provisional Application 60945825 · Jun 22, 2007
Related Publication 20100311639A1 · Dec 9, 2010